HIV-1 testing during labor
This article was originally published in The Gray Sheet
Executive SummaryWidespread rapid HIV testing during labor would be cost-saving to the medical system, according to authors of the CDC-funded, 91,707-patient, Mother-Infant Rapid Intervention At Delivery (MIRIAD) trial. "Our study demonstrates that, in general, results are timely and that antiretroviral prophylaxis can be provided promptly to HIV-infected women and their infants," Marc Bulterys, MD/PhD, CDC, et al., explain in the July 14 issue of JAMA. Rapid HIV-1 tests administered during labor were 100% sensitive and 99.9% specific with a positive predictive value of 90%. Perinatal HIV testing would be especially valuable in the developing world, where "pregnant women with unknown HIV status are often seen by clinicians for the first time during labor," the authors note...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.